Business
NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application
MONTPELLIER, France, December 08, 2025--Regulatory News: NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announces that it has obtained the expected results from the extended characterization program of NFL-101, in accordance with the guidance provided by several European regulatory agencies and the U.S. FDA.
About this update from Nfl Biosciences Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"These results represent the first scientific milestone expected by regulatory agencies and potential pharmaceutical partners","length":124,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":124,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"New patent application currently in preparation","length":47,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":47,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Results obtained in line with the announced timeline","length":52,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":52,"olType":false},{"type":"text","content":"MONTPELLIER, France, December 08, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announces that it has obtained the expected results from the extended characterization program of NFL-101, in accordance with the guidance provided by several European regulatory agencies and the U.S. FDA.","length":370,"tagName":"p"},{"type":"text","content":"These results strengthen intellectual property by consolidating undisclosed internal know-how, while potentially paving the way for additional formal protection, such as a new patent application.","length":195,"tagName":"p"},{"type":"text","content":"NFL-101 is a standardized botanical extract derived from tobacco leaves, developed as a drug candidate for smoking cessation. As a natural product composed of a complex ensemble of constituents, it requires detailed characterization to accurately describe its composition, ensure lot-to-lot reproducibility, and meet the specific expectations of regulatory agencies regarding botanical products. This approach ensures robust analytical control in line with the standards required for this type of drug.","length":502,"tagName":"p"},{"type":"text","content":"The work performed has enabled further refinement of the identification and quantification of NFL-101 constituents. These constituents were subsequently grouped into several chemical families representative of the botanical extract. Taken together, these data now provide a precise de...